


# ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

## Personalized Nanomedicine

### Opportunities for Glyconanomaterials in Personalized Medicine

Niels-Christian Reichardt\*<sup>1,2</sup>, Manuel Martin-Lomas<sup>1</sup>, Soledad Penades<sup>1</sup>

<sup>1</sup>CIC biomaGUNE, Glycotechnology Laboratory, Paseo Miramón 182, 20009 San Sebastian, Spain.

<sup>2</sup>CIBER BBN, Paseo Miramón 182, 20009 San Sebastian, Spain.

\*Correspondence to: [nreichardt@cicbiomagune.es](mailto:nreichardt@cicbiomagune.es) (N.C.R.)

#### Introduction

Traditional medicine at the beginning of the 19<sup>th</sup> century was deeply rooted in two major beliefs: 1. the body was viewed as a collection of parts that were all intimately connected and interlaced, leading to systemic vision of every illness as opposed to a localized model of disease causation and 2. the body was seen as an equilibrated system of input and output, in constant interaction with its environment and illness was as a state of imbalance which had to be readjusted by diet, excretion, perspiration, ventilation or blood-letting. Consequently, among the preferred options for treatment were often those that produced strong and noticeable effects on the patient's body like e.g. mercury chloride (Calomel), which was used as a purgative and diuretic, opium to relieve pain or stop diarrhea, and camphor to induce perspiration.<sup>1</sup>

Lacking the molecular markers and in vivo imaging methods of today's medical practice the physician's diagnosis and prognosis of an illness was based on easily detectable symptoms, experience and perhaps more importantly a continued dialogue with the patient and his family.

The implementation of Descartes' scientific methodology not only revolutionized the natural sciences but with its reductionist approach also transformed medicine into an evidence based and analytical discipline.<sup>2</sup> Applying this approach, clear disease categories were defined for the first time based on a set of common symptoms, reproducible methods for their analysis, and the selective treatment usually of a single most dominant factor. The general success of this approach e.g. in the tremendously efficient treatment of devastating bacterial infections with antibiotics or their prevention by immunization with vaccines clearly justified this idea.

Not all types of diseases however are equally well described and treated by this reductionist approach and a singular focus on a defined disease ignores the often remarkable differences among patients in the response to a particular treatment (Table 1). The efficacy for most prescription drugs are rather moderate and lie between 30-70% depending on the treated disease<sup>3</sup>. For some treatments like chemotherapy or anti-depressive drugs, efficacy can even fall below 25%.<sup>4</sup> The result of these *one-fits-all* therapies has been an unnecessarily high expenditure for prescription drugs due to overtreatment but more importantly, an unjustified large number of patients suffering common drug side effects.


Personalized medicine has been proposed more than a decade ago as a possible solution to overcome some of the shortcomings of current medical practice. It consist largely in an improved patient stratification process to select subpopulations that have a higher probability to benefit from

a particular drug therapy (*..the right drug for the right person..*) and the exclusion of high risk individuals from treatment to reduce the number of patient suffering severe side effects. The

Therapeutic area	Efficacy rate (%)
Alzheimer's Disease	30
Analgesics (Cox-2)	80
Asthma	60
Cardia Arrythmias	60
Depression (SSRI)	62
Diabetes	57
HCV	47
Incontinence	40
Migraine (acute)	52
Migraine (prophylaxis)	50
Oncology	25
Osteoporosis	48
Rheumatoid arthritis	50
Schizophrenia	60

**Table 1.** Efficacy of common drug treatments. Table adapted from reference 4

emphasis in today's personalized medicine approach from an industrial perspective relies on diagnostics and risk assessment to improve the choice among existing treatment options rather than on the development of individual treatment options for very small patient populations which are commercially unattractive as seen by low industry interest in rare diseases. Currently personalized medicine is focused largely on genomic markers for patient stratification. While genomic disease markers are efficient in classifying patients based on hereditary risk factors and traits, they are less indicative in describing more dynamic risk factors which are influenced by the environment, diet, habits or the patient's gender or age. Here the profiling of other biomolecules like oligosaccharides, lipids or metabolites with a generally significantly smaller repertoire of relevant structures than proteins, genes or RNA, integrated in a omics-wide analysis of a disease is likely to provide a clearer picture of the physiological condition that relates to a differentiated drug response and hence allow patient classification into subgroups for personalized treatment (see Figure 1)




**Figure 1.** Integration of glycomics and glycoproteomics for the detection of aberrant glycosylation e.g. in cancer into an omics-wide approach will be critical for improving diagnosis and personalized treatment. Reprinted from reference 5 with permission from Elsevier.

As biomarkers, glycans present a number of advantages over other biomolecules<sup>6</sup>: Being a non-template controlled process glycosylation is more strongly affected by environmental factors and physiological changes than e.g. protein expression. Glycan biosynthesis is also spatially limited to Golgi and endoplasmic reticulum (ER), resulting in more uniform changes of glycosylation with disease on a cellular level. Finally, the usually on average higher molecular weight of glycans compared to metabolites and a generally higher structural homogeneity present advantages for the analysis and quantification of glycans.

As an example for a glycan biomarker, the DG9-glycan index, defined as the ratio of fucosylated to nonfucosylated triantennary glycans, provided optimal discrimination between two groups of subjects with different diabetes types according to a recent study.<sup>7</sup> Efforts are also underway to integrate disease related information from biomarkers studies into general glycan databases like Unicarb KB<sup>8</sup>

In this feature article we discuss the particular relevance of glycans as components or targets of functionalized nanoparticles (NPs) for potential applications in personalized medicine but we will not enter into descriptions for their preparation. For more general view covering the preparation and applications of glyconanomaterials the reader is referred to a number of recent reviews<sup>9–11</sup>. The combination of glyco- and nanotechnology is already providing promising new tools for more personalized solutions to diagnostics and therapy<sup>12–15</sup>. Current applications relevant to personalized medicine include drug targeting, localized radiation therapy, imaging of glycan expression on cancer cells, point of care diagnostics, cancer vaccines, photodynamic therapy, biosensors, glycoproteomics.

Glycans are ubiquitously distributed in all body tissues, and have important functions at a cellular level. Hence, any artificial nano-sized system for *in vivo* drug delivery or imaging should take advantage of the remarkable properties glycans offer to improve its biocompatibility or to facilitate tissue selective targeting.<sup>9</sup> To fully understand the potential of glycans for functionalisation of nanomaterials it is important to recall the multiple functions glycans exert in nature on a cellular level (Figure 2).



**Figure 2.** Functions and roles of glycans on nanomaterials


With over 200 glycosyltransferases involved in the biosynthesis of our glycome, defined as the collection of glycans found in one single species, our body invests heavily in the continued production of glycans underlining the importance of this class of biomolecules.<sup>16</sup>

Attached to a peptide or lipid backbone glycans interact specifically with carbohydrate specific receptors termed lectins on other cells facilitating enabling reversible and tuneable cell-cell adhesion, a process that is important for e.g. for leukocyte targeting to infected tissue, in sperm-egg fertilization, but also in the infection through pathogens. This dense glycan coat on the extracellular surface is for other cells, parasites, viruses or bacteria the first line of contact with a mammalian host and in a constant co-evolutionary struggle pathogens have developed a number of ways to exploit glycans to evade recognition by the immune system or to overcome the glycan shield for infection<sup>17,18</sup>.

#### Targeting antigen presenting cells

Antigen presenting cells (APCs) like macrophages, dendritic cells or Langerhans cells are the sentinels of the human immune system and an important link between innate and adaptive immunity. They

express a considerable number of carbohydrate binding surface receptors called C-type lectins (CLRs) that internalise pathogenic but also endogenous glycoconjugates and cross-present them to naïve Tcells. As an example, DC-SIGN, a CLR that preferentially binds fucosylated and high mannose structures has been shown to be an entry portal for viruses like HIV, hepatitis, Marburg or Dengue into dendritic cells.<sup>19</sup> The clustering of DC-SIGN into lipid raft microdomains facilitates binding to large antigens with viral dimensions through a strong multivalent interaction e.g. with the envelope glycoproteins<sup>20</sup> (Figure 3).



**Figure 3.** DC-SIGN receptor clustering in microdomains enhances binding of virus-sized particles with respect to isolated DC-SIGN molecules. Reproduced from reference 20 with permission by Rockefeller University Press.

Consequently, blocking and sequestration of DC-SIGN cell surface receptors was accomplished with multivalent gold glyconanoparticles that had been functionalized with high mannose glycans of varying complexity mimicking the glycan shield of the gp120 HIV envelope protein and efficiently inhibiting the entry of HIV into dendritic cells.<sup>21,22</sup>

### Immunomodulation

Some pathogens express host-like glycan structures on their cells in a form of *molecular mimicry* to evade recognition by the host immune system.<sup>23</sup> Helminthic parasites for example can target specific receptors located on host immune cells with host-like glycans to dampen the host immune response to their own benefit.<sup>24</sup> Within their often complex life cycle which can span several different hosts, parasites adjust to the changing environmental conditions by dynamic changes in their cell surface glycosylation.<sup>25</sup> The dynamic and varied structural expression of glycans is also a result of the million years of co-evolution between pathogens and their hosts and a strategy to counterbalance the rapid adaption of pathogens to a changing environment by unchallenged faster replication cycles.<sup>17</sup> In light of the ubiquitous presence of carbohydrate binding proteins on immune cells, the selection of glycan structures for protecting nanomaterials for in vivo use should be guided taking into account the binding specificities of these lectins to either avoid a rapid decrease of circulating nanoparticles or rather to exploit the glycan-mediated internalisation of nanoparticles for immune cell targeting. The Penades group employed glucose as a major non-immunogenic carbohydrate




component responsible for the excellent water solubility in the design of their glyconanoparticles.<sup>26,27</sup> On the other hand the systemic administration of glyconanoparticles functionalised with the readily available monosaccharides galactose, fucose, N-acetylglucosamine or mannose has been shown to give rise to a tissue-dependant biodistribution.<sup>28</sup> Also, glucose-functionalised particles can be concentrated in tissue overexpressing glucose transporters thereby leading to an uneven biodistribution of particles. This interaction between systemically administered glucose/folate functionalised gold nanoparticles with membrane bound glucose transporters and folate receptors that are both overexpressed in cancer, was exploited for targeted drug delivery to ovarian tumours.<sup>29</sup> Likewise, glucose-functionalised gold nanoparticles also in combination with a neuropeptide ligand have been shown to enhance the crossing of the blood brain barrier presumably via a glucose transporter mediated uptake mechanism.<sup>27</sup> These examples show that even sugars with a seemingly low profile in molecular recognition processes like glucose can be used for directed targeting or in other terms should be assessed for potential off-target effects.

### Tumour Targeting

Cell surface glycosylation is ubiquitous, species and tissue specific. In addition, changes in glycosylation like an increase in sialylation or fucosylation of cell surface glycans are a hallmark of many cancer cells and thought to play a functional role in metastasis, the migration of individual cancer cells from the tumour to other tissues. Consequently, targeting of cell surface glycans is a promising strategy for concentration of nanomaterials in tumor tissue or specific organs for imaging or therapeutic purposes.

In a form of *leukocyte mimicry* metastasizing tumour cells are thought to target and adhere to endothelial tissue far away from the parent tumour via selectin mediated binding to the same glycan sialyl-Le<sup>x</sup>.<sup>30</sup> The overexpression of a 2,6 sialyltransferase in human breast cancer cells has been associated with an increased adhesion to and passage through the blood brain barrier possibly through P- and E-selectin mediated cell-cell adhesion. E and P selectins are overexpressed on inflamed vascular tissue and an early marker e.g. in brain lesions, that can be imaged by MRI with silica core shell superparamagnetic and iron oxide dextran coated nanoparticle based contrast agents carrying sLeX ligands, the natural selectin ligand.<sup>31,32</sup> Likewise, the interaction of hyaluronic coated iron oxide nanoparticles with the cell surface receptor CD44 over-expressed on cancer cells has been exploited in imaging of tumours by MRI.<sup>33</sup>



**Figure 4.** Chemical structure of example glycans employed as biomarkers and in anti-cancer vaccines.

Mucins are large gel-forming and heavily glycosylated glycoproteins with primary functions in lubrication and protection of epithelial tissues but they are also involved in cell differentiation, signalling and cell adhesion.<sup>34</sup> Mucins are overexpressed in a large number of cancers and accompanied by an aberrant glycosylation profile presenting unique truncated structures like sialyl-Tn antigen (Figure 4). Aberrant mucin glycosylation is currently being developed for improved cancer diagnostics and has been a molecular target for a large number of immunotherapeutic approaches including several anti-cancer vaccines.<sup>35</sup> The current dogma of glycan based immunisation requires small carbohydrate antigens to be coupled to a peptide or protein carrier for the effective cross-presentation to naïve T cells by major histocompatibility complex (MHC) I or II leading to clonal expansion of T cells. A recent example however shows that a selective and immune response that is cross-reactive to natural mucins can also be elicited with a peptide free system. Parry et al. attached Tn-antigen functionalized polymers of defined length and carbohydrate copy number onto gold nanoparticles to produce a highly multivalent antigen presentation. Injected into rabbits some of these constructs were able to elicit a Tn-antigen specific immune response that was cross-reactive with natural mucin, albeit less effective than constructs attached to a T-helper peptide or carrier toxin.<sup>36</sup> Nevertheless, the failure of a large phase III sialyl-Tn/KLH vaccine trial to treat breast cancer highlighted the strong variation of sialyl-Tn expression among patients. A prior stratification of patients according to their sialyl-Tn expression level would most likely increase the number of patients benefitting from these types of therapies.<sup>37</sup>



Where the analysis of cell surface receptor density is an analytical challenge or not possible, theranostic nanoparticles<sup>14,38</sup> that release their drug or vaccine cargo only upon encountering the minimal threshold density of surface receptors required for efficacy could minimize side effects and increase the number of responders to a particular treatment. For such an in-vivo diagnostics and treatment platform, drug release mechanisms that respond to a receptor density threshold have to be developed. Multivalent effects between glycan functionalized nanoparticles and protein receptors could provide such a general mechanism for the selective adhesion to cell presenting a specific surface receptor at a minimal density.<sup>39</sup>

### Inhibitors of pathogen adhesion

The dense cloak of glycans is also frequently an attachment point of pathogens like bacteria, parasites or viruses initiating the infection. The interaction with host cell surface glycans is mediated by specific carbohydrate binding receptors termed lectins which are often found concentrated on the pili of bacteria mediating adhesion.<sup>40</sup> *Pseudomonas aeruginosa*, a bacterial pathogen primarily causing lung damage, invades host cells by a lipid zipper mechanism that operates via a clustering of the host cell surface glycolipid Gb3 by the bacterial lectin LecA.<sup>41</sup>

Numerous examples of glyconanomaterials that selectively bind to uropathogenic *Escherichia coli* with potential for pathogen identification, and as antiadhesives to prevent infection and biofilm formation by have been described.<sup>42–44</sup> More recently, trimeric cluster thiomannosides conjugated to diamond nanoparticles have been shown to inhibit type 1 fimbriae-mediated *E. coli* adhesion and biofilm formation<sup>45</sup> and mannose-coated single wall carbon nanotubes (SWCNTs) were able to reduce 10 % the colony formation of *E. coli* ORN178 strain.<sup>46</sup>

The carbohydrate-lectin mediated entry of pathogens has spurred the development of a large number of multivalent carbohydrate display systems including glyconanomaterials as potential inhibitors of this adhesion process. Recent examples include a trideca-fullerene functionalised with 120 mannose residues as a nanomolar inhibitor of virus adhesion in an Ebola infection model<sup>47</sup> or mannose functionalised glyconanoparticles interfering with LecB binding of *Pseudomonas aeruginosum*, an important process in the formation of biofilms,<sup>48</sup> and inhibit the HIV trans infection of dendritic cells to T cells.<sup>21</sup>

The influenza virus makes extensive use of sialic acid derived glycans on the host cell surface in its replication cycle. It first attaches to host lung tissue rich in alpha 2,3-sialosides via the envelope proteins hemagglutinin (HA) initiating the endocytosis of the virus. After replication in the cell the budding virus detaches from the host cell again now cutting the bonding host sialic acids with a specific sialidase to be able to move on for the next infection.<sup>49</sup> For some time a number of groups have been developing sialic acid (SA) modified polymers and nanoparticles to intervene in the HA-SA acid interaction and protect against influenza infection.<sup>50,51</sup>

### Stealth

Next to their more intriguing roles in cellular communication cell surface glycans also behave as an efficient physical barrier against the entry of bacterial or viral pathogens, protect proteins against protease degradation and can increase significantly protein solubility by reducing non-specific interactions with other proteins.

Glycosylated plasma proteins like haptoglobin or antitrypsin with a high carbohydrate content and homogenous glycan distribution are most effectively protected against adsorption on hydrophobic interfaces.<sup>52</sup>


Surface glycosylation has consequently been employed in many materials to enhance biocompatibility, solubility and to add targeting functionality. This has been particularly important for enabling the use of the very hydrophobic carbon allotropes graphene, fullerenes or carbon nanotubes for biological and biomedical applications.<sup>10</sup> The functionalisation of nanomaterials produced for *in vivo* applications in imaging, radiation therapy or drug delivery with glycans is also an efficient strategy to reduce the non-specific adsorption of plasma proteins on the nanomaterial surface, which can alter significantly their physiological response affecting agglomeration, cellular uptake, or reduce their circulatory half life by opsonisation.<sup>53</sup>


The spontaneous, dynamic and largely unpredictable adsorption of plasma proteins to surfaces termed *protein corona formation* has been recognized as the single most important hurdle for clinical applications of nanomaterials and strategies for reducing non-specific adsorption are in high demand.<sup>54</sup> Complement plasma proteins and IgGs adsorb to insufficiently protected non-stealth particles and label them for the rapid removal within seconds by macrophages of the mononuclear phagocytic system (opsonisation).<sup>55</sup> This process poses a major challenge for the development of drug delivery systems with increased circulatory half life based on polymeric nanoparticles. Adsorption of proteins like fibrinogen or ribonuclease A to nanomaterials can also lead to a destabilisation of their structure e.g. by partial unfolding altering their function and promoting particle aggregation.<sup>56–58</sup> This does not seem to be a universal process. For instance protein adsorption on nanoparticles with high curvature actually improves protein stability and retains enzymatic functions as examples for soy bean peroxidase, lysozyme and human carbonic anhydrase have shown.<sup>56</sup> Precoating of nanoparticles with a single protein like albumin has been shown to increase colloidal stability and reduce binding of opsonins (C3, IgGs) consequently reducing nanoparticle uptake by macrophages.<sup>59</sup> Protein coating of nanomaterials can also be further exploited for the attachment and proteolytic release of drugs.<sup>60,61</sup>

An increasing number of studies have revealed that the composition and presence of protein corona is dependent on nanoparticle size, charge, shape, surface functionalization and incubation time.<sup>54,62–71</sup> While most studies had suggested a limited complexity of protein coronas of several dozens proteins a recent quantitative proteomic study identified up to 300 different proteins in the protein corona of silica and polystyrene nanoparticles.<sup>68</sup> Protein adsorption from serum occurred within minutes and the corona composition changed little with prolonged exposure time. In addition the authors observed that the particle net charge after corona formation was negative independent of the initial particle charge.<sup>68,69</sup> The great majority of studies have analysed protein corona formation *in vitro* largely due to the difficulties involved in isolating nanoparticles after *in vivo* exposure.<sup>54</sup> In a recent paper however the authors report on the use of iron oxide nanoparticles that are isolated from rat sera with the help of a strong magnetic field to analyse and compare *in vitro* with *in vivo* protein corona formation. Their findings suggest significant differences in protein corona composition highlighting the limitations of *in vitro* assays for correct simulations of this biomedically so relevant process.<sup>72</sup>

Heparin is an inhibitor of the complement system and was covalently linked to polymethylmetacrylate (PMMA) nanoparticles to enhance circulatory half-life of nanoparticles and circumvent opsonisation.<sup>73</sup>

The majority of serum proteins are glycosylated and as mentioned above glycosylation affects circulatory half-life, stability and function. It therefore comes as no surprise that glycosylation also has a major impact on the colloidal stability of nanoparticles coated with a protein corona and affects the interaction between cells and nanoparticles as a recent report by Wan et al. shows.<sup>74</sup> Protein corona coated nanoparticles were incubated with a mixture of glycosidases for varying time lengths and the impact of reduced protein glycosylation on colloidal stability and cell nanoparticle interaction was measured. Partial removal of glycans from the hard protein corona led to a progressive decrease in colloidal stability most probably due to the loss of the repellent functions of the outer glycan coating facilitating non-specific interactions between protein interfaces that ultimately destabilizes the nanoparticle protein complexation.<sup>74</sup> The deglycosylated corona nanoparticles also adhered more strongly to macrophage membranes leading to an increased NP uptake. In addition, uptake of deglycosylated corona NPs by both M1 and M2 macrophages led to an increased expression of the pro-inflammatory cytokines hIL-1 $\beta$  and hTNF- $\alpha$  compared to the fully glycosylated corona NPs. In a recent study the groups of Penades and Liz-Marzan assessed the protective effect of glycan ligands for suppressing protein corona formation on gold nanorods. Lactose functionalised nanorods, GlcNAc functionalised gold NPs and PEG-functionalised nanomaterials showed a similar strongly reduced protein adsorption compared to charged citrate stabilised nanoparticles and rods, which rapidly formed complex protein coronas, highlighting the excellent repellent properties of glycans in protein rich media.<sup>64</sup> A macrophage uptake assay comparing lactose and PEG functionalization showed a rapid uptake of pegylated gold nanorods while lactose efficiently prevented phagocytosis.<sup>64</sup> (Figure 5) These findings seem to be in line with a recent report by Schöttler et al. showing a stealth protection of pegylated nanostructures against cellular uptake only in the presence of proteins adsorbing to the PEG-layer.<sup>75</sup> An analysis of the protein corona of pegylated nanoparticles after exposure to plasma proteins showed selective adhesion of a high amount of clustering an apolipoprotein that reduced uptake by macrophages by up to 75%. These examples also demonstrate that certain glycans unlike PEG or other polymers used as protection of nanomaterials against non-specific protein adsorption do not require a specific protein coating to exert their stealth effect.





**Figure 5.** TEM images of GlcNAc-coated spherical gold nanoparticles AuNPs@GlcNAc and lactose-coated gold nanorods (AuNRs@Lac). Illustrative examples of the behaviour of fluorescent-labelled lactose- or polyethylene glycol-coated gold nanorods (AuNRs@Lac-F647 and AuNRs@PEG-F647) internalized by macrophage-like J774 cells over time at 37 °C, 5% CO<sub>2</sub>. The pink colour indicates the presence of nanoparticles, whereas blue colour denotes the nuclei. Adapted from reference 64 with permission. Copyright public domain

The *in situ* formation of gold or silver nanoparticles with polysaccharides as a reduction and/or passivation agent can be regarded as an alternative and particularly green chemistry method for the functionalization of nanoparticles with glycans.<sup>76</sup> To this end various polysaccharides including starch, chitosan and carboxymethylcellulose or dextran have been employed in the preparation of noble metal nanoparticles<sup>77</sup> with good stability, water solubility and biocompatibility. Single wall carbon nanotubes, which are highly insoluble in aqueous media have been solubilised by wrapping them in polysaccharides like starch or Arabic gum.<sup>78,79</sup> The iodine embedded inside a helical amylase polysaccharide was displaced by a single or bundles of carbon nanotubes while the charged Arabic

gum polysaccharide spontaneously coated the hydrophobic carbon nanotubes in a process that involved also the exfoliating of carbon nanoropes into single tubes.<sup>78</sup>

This early work on glycan functionalized nanomaterials demonstrates the potential of glycans and glycan mixtures for in tissue targeting and for the passivation against non-specific protein adsorption. Many approaches to protect nanomaterials against agglomeration and non-specific protein adsorption employ polyethyleneglycol, a material with generally low toxicity. As the extended use of polyethylene glycol as a common additive in cosmetics and drugs has been recently found to cause a anti-PEG directed immune response in nearly a quarter of the population<sup>80</sup> the use of PEG-based surfactants in the preparation of nanomaterials for *in vivo* use should at least be reconsidered.

### **Vesicular Trafficking**

Glycosylation plays an important role in trafficking proteins to apical and basolateral membranes and recent studies suggest also an involvement in protein trafficking to exosomes.<sup>81</sup>

Exosomes are 40-100 nm sized vesicles secreted by wide range of mammalian cells as vehicles for intercellular trafficking of cellular components including miRNA, mRNA, proteins, metabolites etc. Glycan analysis of exosomes and source tissues revealed a conserved glycan repertoire for exosomes which could help guide exosomes between different tissues via carbohydrate lectin interactions.<sup>81</sup> Isolated and modified exosomes have been proposed as vehicles for drug and gene delivery but the vesicle loading with cargo is still insufficient.<sup>82</sup> Formation of vesicles by self-assembly approaches with natural or synthetic lipids and block polymers circumvents a cargo loading step as drugs or genes for delivery are encapsulated in the assembly step. In addition, exosome mimetics prepared in this manner allow at least theoretically a defined functionalization of the exosome surface with targeting and stealth ligands.<sup>83,84</sup>

### **Extracellular matrix glycans for sequestering and storing proteins**


Glycosaminoglycans (GAGs) like heparan sulfate, chondroitin and dermatan sulfate are highly sulfated linear polysaccharides located within the extracellular space. Apart from physical functions in tissue hydration, as lubricants or protein stabilizers many GAGs are also key biological response modifiers<sup>85</sup> that can engage in specific interactions with growth factors, cytokines and enzymes, act as signalling molecules in wound repair, tumorigenesis and infection or facilitate host cell invasion by pathogenic microbes.<sup>86</sup> The Linhardt group prepared gold and silver nanoparticles via reduction of silver and gold salts in the presence of heparin and hyaluronic acid both as a coating and reducing agents. Hyaluronic acid and heparin coatings led to a stabilization of nanoparticles in physiological media while maintaining their anticoagulant and anti-inflammatory properties.<sup>87</sup> Proteoglycans like aggrecan can sequester and stabilize proteins like growth factors by specific interactions between protein and the charged polysaccharide. A recent report from the Kipper group describes the use of heparin functionalised nanoparticles as vehicles for growth factor delivery. Mimicking natural aggrecan, the heparin functionalized nanoparticles readily complexed and stabilized growth factors like FGF1 for delivery and continued slow release as long as a month.<sup>88</sup>

### **Molecular gates**

Glycans have also been employed as molecular gates for the enzymatically stimulated release of cargo from mesoporous nanoparticles. Agostini et al. developed mesoporous silica nanoparticles functionalized with galactooligosaccharides (GOS) as functional gates to close the pores and retain a



fluorophore cargo within the nanostructure.<sup>89</sup> Specific enzymatic hydrolysis of the GOS gates by beta-galactosidase opened the pores and released the trapped fluorophore from the mesoporous particles (Figure 6). High beta galactosidase activity is characteristic for senescent cells, which are cells that have reached their limit of possible divisions and due to their changed phenotype constitute a threat for the growth and development of surrounding healthy cells. Agostini et al. exploited the beta-galactosidase stimulated release of the gated fluorophore from mesoporous particles to detect senescent cells *in vitro*. This principle of cell-type specific cargo release might be further developed for the release of a telomere reactivation or a cytotoxic drug for *in vivo* therapy. A similar approach



**Figure 6.** Release of fluorophores from galacto-oligosaccharide gated mesoporous nanoparticles. Reproduced from reference 89 with permission from John Wiley and Sons.

for the release of a toxic drug from its nanoparticle protection was developed by the Duncan group. The neurotoxicity of phospholipase A2, a snake venom, that had shown otherwise good efficacy in phase 1 clinical trials for the treatment of breast cancer was significantly reduced by covalent coupling to dextran nanoparticles.<sup>90</sup> The masked toxin was liberated by the enzymatic hydrolysis of the dextran carrier through alpha amylase which is overexpressed in tumour cells.

## Imaging

Patient stratification into responders and non-responders is a key principle of personalized medicine that requires sensitive diagnostic methods. *In vivo* imaging techniques like magnetic resonance imaging (MRI), positron emission tomography (PET) or fluorescence imaging are non-invasive and could be harnessed to provide a spatio-temporal distribution of analytes in contrast to the measurement of isolated single parameters (biomarkers). Due to their optical and magnetic properties, their small size that allows penetration of most tissues and their large aspect ratios for the attachment of functional molecules with high density, metal nanomaterials are ideally suited as contrast agents in many imaging modalities.<sup>91</sup> Lectins have been used for many years in the histological examination of tissue samples e.g. to detect and quantify changes in glycosylation in tumours.<sup>92</sup> Recently lectins have also made their way into nanoparticle based *in vivo* imaging of the glycan distribution of mice brains.<sup>93</sup> Gao et al. encapsulated CdSe/ZnS quantum dots into PEG-PLA nanoparticles and functionalized them covalently with wheat germ agglutinin, a lectin recognizing GlcNAc and sialic acid to improve delivery to the brain after administration through the nasal mucus

which is rich in sialic acid presenting glycans. The particles were efficiently delivered to the brain, allowing imaging for over 4h and were nearly completely cleared after 8h suggesting a good safety profile for their use as imaging agents. The cytotoxicity and often promiscuous binding patterns of many lectins has limited their widespread use for *in vivo* imaging applications. The discovery of highly selective lectins capable of recognizing larger glycan structures<sup>94</sup> and the recombinant engineering of non-toxic lectins<sup>95</sup> are addressing these current limitations opening the door to a new generation of *in vivo* glycan imaging agents.

### Glyconanotechnology as an enabling technology for personalized medicine

As we have seen glycans are ubiquitously distributed in all body tissues, and have important functions at a cellular level. Hence any artificial nanosized system for *in vivo* drug delivery or imaging should take advantage of the remarkable properties glycans offer to improve biocompatibility and facilitate tissue selective targeting. Here, we have focused on those applications of glyconanotechnology which have made or are likely to make an impact on the development of more personalized diagnostics and therapies, features that make nanomaterials *fit for purpose*.

The combination of glyco- and nanotechnology is already providing promising new tools for more personalized solutions to diagnostics and therapy. Glycans can play a central role as antigens or targeting probes for nanoparticle applications in oncology and immunology, but also open up opportunities for other areas where the unparalleled stealth properties and usually low immunogenicity of glycans may be valuable assets for any nanomaterial designed for biomedical use.

**Acknowledgements:** We acknowledge generous funding from the Spanish Ministry of Economy and Competitiveness MINECO (grant number: CTQ2014-58779-R). This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 642870 (ETN-Immunoshape).

### References:

1. C. E. Rosenberg, *Milbank Quarterly*, 2002, **80**, 237–260.
2. A. C. Ahn, M. Tewari, C.-S. Poon, and R. S. Phillips, *PLoS Med.*, 2006, **3**, e208.
3. S. Bates, *Drug Discov. Today*, 2010, **15**, 115–20.
4. B. B. Spear, M. Heath-Chiozzi, and J. Huff, *Trends Mol. Med.*, 2001, **7**, 201–204.
5. A. Almeida and D. Kolarich, *Biochim. Biophys. Acta*, 2016, **1860**, 1583–1595.
6. C. B. Lebrilla and H. J. An, *Mol. Biosyst.*, 2009, **5**, 17–20.
7. G. Thanabalasingham, J. E. Huffman, J. J. Kattla, M. Novokmet, I. Rudan, A. L. Gloyn, C. Hayward, B. Adamczyk, R. M. Reynolds, A. Muzinic, and others, *Diabetes*, 2013, **62**, 1329–1337.



8. M. P. Campbell and N. H. Packer, *Biochim. Biophys. Acta*, 2016, **1860**, 1669–75.
9. N. C. Reichardt, M. Marttín-Lomas, and S. Penadés, *Chem. Soc. Rev.*, 2013, **42**, 4358–4376.
10. B. K. Gorityala, J. Ma, X. Wang, P. Chen, and X.-W. Liu, *Chem. Soc. Rev.*, 2010, **39**, 2925–34.
11. K. El-Boubbou and X. Huang, *Curr. Med. Chem.*, 2011, **18**, 2060–2078.
12. L. J. Peek, C. R. Middaugh, and C. Berkland, *Adv. Drug Deliv. Rev.*, 2008, **60**, 915–28.
13. H. Lee, K. Lee, I. K. Kim, and T. G. Park, *Biomaterials*, 2008, **29**, 4709–4718.
14. J. H. Ryu, S. Lee, S. Son, S. H. Kim, J. F. Leary, K. Choi, and I. C. Kwon, *J. Control Release*, 2014, **190**, 477–484.
15. H.-L. Zhang, X.-L. Wei, Y. Zang, J.-Y. Cao, S. Liu, X.-P. He, Q. Chen, Y.-T. Long, J. Li, G.-R. Chen, and others, *Adv. Mater.*, 2013, **25**, 4097–4101.
16. A. S. Opat, C. van Vliet, and P. A. Gleeson, *Biochimie*, 2001, **83**, 763–773.
17. A. Varki, *Cell*, 2006, **126**, 841–5.
18. J. R. Bishop and P. Gagneux, *Glycobiology*, 2007, **17**, 23R–34R.
19. T. B. Geijtenbeek, D. S. Kwon, R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, J. Middel, I. L. Cornelissen, H. S. Nottet, V. N. KewalRamani, D. R. Littman, C. G. Figdor, and Y. van Kooyk, *Cell*, 2000, **100**, 587–597.
20. A. Cambi, F. de Lange, N. M. van Maarseveen, M. Nijhuis, B. Joosten, E. M. H. P. van Dijk, B. I. de Bakker, J. A. M. Fransen, P. H. M. Bovee-Geurts, F. N. van Leeuwen, N. F. Van Hulst, and C. G. Figdor, *J. Cell Biol.*, 2004, **164**, 145–55.
21. O. Martínez-Avila, L. M. Bedoya, M. Marradi, C. Clavel, J. Alcamí, and S. Penadés, *Chembiochem*, 2009, **10**, 1806–9.
22. B. Arnáiz, O. Martínez-Ávila, J. M. Falcon-Perez, and S. Penadés, *Bioconjug. Chem.*, 2012, **23**, 814–25.
23. E. Severi, D. W. Hood, and G. H. Thomas, *Microbiology*, 2007, **153**, 2817–2822.
24. I. van Die and R. D. Cummings, *Glycobiology*, 2010, **20**, 2–12.
25. A. van Remoortere, C. H. Hokke, G. J. van Dam, I. van Die, A. M. Deelder, and D. H. van den Eijnden, *Glycobiology*, 2000, **10**, 601–609.
26. R. Ojeda, J. L. de Paz, A. G. Barrientos, M. Martín-Lomas, and S. Penadés, *Carbohydr. Res.*, 2007, **342**, 448–59.
27. J. Frigell, I. Garcia, V. Gómez-Vallejo, J. Llop, and S. Penadés, *J. Am. Chem. Soc.*, 2013, **136**, 449–457.

28. K. El-Boubbou, D. C. Zhu, C. Vasileiou, B. Borhan, D. Prosperi, W. Li, and X. Huang, *J. Am. Chem. Soc.*, 2010, **132**, 4490–4499.
29. M. H. El-Dakdouki, J. Xia, D. C. Zhu, H. Kavunja, J. Grieshaber, S. O'Reilly, J. J. McCormick, and X. Huang, *ACS Appl. Mater. Interfaces*, 2014, **6**, 697–705.
30. I. P. Witz, *Cancer Treat. Res.*, 2006, **130**, 125–40.
31. T. D. Farr, C.-H. Lai, D. Grünstein, G. Orts-Gil, C.-C. Wang, P. Boehm-Sturm, P. H. Seeberger, and C. Harms, *Nano Lett.*, 2014, **14**, 2130–4.
32. S. I. van Kasteren, S. J. Campbell, S. Serres, D. C. Anthony, N. R. Sibson, and B. G. Davis, *Proc. Natl. Acad. Sci. U S A*, 2009, **106**, 18–23.
33. Y. Lee, H. Lee, Y. B. Kim, J. Kim, T. Hyeon, H. Park, P. B. Messersmith, and T. G. Park, *Adv. Mater.*, 2008, **20**, 4154–4157.
34. M. Andrianifahanana, N. Moniaux, and S. K. Batra, *Biochim. Biophys. Acta*, 2006, **1765**, 189–222.
35. D. Feng, A. S. Shaikh, and F. Wang, *ACS Chem. Biol.*, 2016, **11**, 850–63.
36. A. L. Parry, N. A. Clemson, J. Ellis, S. S. Bernhard, B. G. Davis, and N. R. Cameron, *J. Am. Chem. Soc.* 2013, **135**, 9362–9365.
37. D. Miles, H. Roché, M. Martin, T. J. Perren, D. A. Cameron, J. Glaspy, D. Dodwell, J. Parker, J. Mayordomo, A. Tres, J. L. Murray, and N. K. Ibrahim, *Oncologist*, 2011, **16**, 1092–100.
38. R. Kojima, D. Aubel, and M. Fussenegger, *Curr. Opin. Chem. Biol.*, 2015, **28**, 29–38.
39. T. K. Dam and C. F. Brewer, *Glycobiology*, 2010, **20**, 270–279.
40. A. Audfray, A. Varrot, and A. Imberty, *C. R. Chim.*, 2013, **16**, 482–490.
41. T. Eierhoff, B. Bastian, R. Thuenauer, J. Madl, A. Audfray, S. Aigal, S. Juillot, G. E. Rydell, S. Müller, S. de Bentzmann, A. Imberty, C. Fleck, and W. Römer, *Proc. Natl. Acad. Sci. U.S.A.*, 2014, **111**, 12895–900.
42. K. El-Boubbou, C. Gruden, and X. Huang, *J. Am. Chem. Soc.*, 2007, **129**, 13392–3.
43. M. Hartmann, P. Betz, Y. Sun, S. N. Gorb, T. K. Lindhorst, and A. Krueger, *Chem. Eur. J.*, 2012, **18**, 6485–6492.
44. N. P. Pera and R. J. Pieters, *MedChemComm*, 2014, **5**, 1027–1035.
45. M. Khanal, F. Larssonneur, V. Raks, A. Barras, J.-S. Baumann, F. A. Martin, R. Boukherroub, J.-M. Ghigo, C. O. Mellet, V. Zaitsev, and others, *Nanoscale*, 2015, **7**, 2325–2335.
46. J. C. Martín, M. Assali, E. Fernández-García, V. Valdivia, E. Sánchez-Fernández, J. G. Fernández, R. Wellinger, I. Fernández, and N. Khiar, *J. Mater. Chem. B*, 2016, **4**, 2028–2037.

47. A. Muñoz, D. Sigwalt, B. M. Illescas, J. Luczkowiak, L. Rodriguez-Pérez, I. Nierengarten, M. Holler, J.-S. Remy, K. Buffet, S. P. Vincent, and others, *Nature Chem.*, 2016, **8**, 50–57.
48. M. Reynolds, M. Marradi, A. Imberty, S. Penadés, and S. Pérez, *Chem. Eur. J.*, 2012, **18**, 4264–4273.
49. M. von Itzstein, *Nat. Rev. Drug Discov.*, 2007, **6**, 967–974.
50. M. Mammen, G. Dahmann, and G. M. Whitesides, *J. Med. Chem.*, 1995, **38**, 4179–90.
51. J. J. Landers, Z. Cao, I. Lee, L. T. Piehler, P. P. Myc, A. Myc, T. Hamouda, A. T. Galecki, and J. R. Baker, *J. Infect. Dis.*, 2002, **186**, 1222–30.
52. J. D. Andrade and V. Hlady, *Ann. N. Y. Acad. Sci.*, 1987, **516**, 158–72.
53. M. Rahman, S. Laurent, N. Tawil, L. Yahia, and M. Mahmoudi, in *Protein-Nanoparticle Interactions*, Springer, 2013, pp. 21–44.
54. S. Zanganeh, R. Spitler, M. Erfanzadeh, A. M. Alkilany, and M. Mahmoudi, *Int. J. Biochem. Cell Biol.*, 2016, **75**, 143–147.
55. D. E. Owens and N. A. Peppas, *Int. J. Pharm.*, 2006, **307**, 93–102.
56. W. Shang, J. H. Nuffer, J. S. Dordick, and R. W. Siegel, *Nano Lett.*, 2007, **7**, 1991–1995.
57. S. Dominguez-Medina, L. Kisley, L. J. Tauzin, A. Hoggard, B. Shuang, A. S. DS Indrasekara, S. Chen, L.-Y. Wang, P. J. Derry, A. Liopo, and others, *ACS Nano*, 2016.
58. Z. J. Deng, M. Liang, M. Monteiro, I. Toth, and R. F. Minchin, *Nat. Nanotechnol.*, 2011, **6**, 39–44.
59. V. Mirshafiee, R. Kim, S. Park, M. Mahmoudi, and M. L. Kraft, *Biomaterials*, 2016, **75**, 295–304.
60. A. Aires, S. M. Ocampo, D. Cabrera, L. de la Cueva, G. Salas, F. J. Teran, and A. L. Cortajarena, *J. Mater. Chem. B*, 2015, **3**, 6239–6247.
61. M. Chanana, P. Rivera Gil, M. A. Correa-Duarte, L. M. Liz-Marzán, and W. J. Parak, *Angew. Chem. Int. Ed. Engl.*, 2013, **52**, 4179–83.
62. S. Winzen, S. Schoettler, G. Baier, C. Rosenauer, V. Mailaender, K. Landfester, and K. Mohr, *Nanoscale*, 2015, **7**, 2992–3001.
63. S. Ju and W.-S. Yeo, *Nanotechnology*, 2012, **23**, 135701.
64. I. García, A. Sánchez-Iglesias, M. Henriksen-Lacey, M. Grzelczak, S. Penadés, and L. M. Liz-Marzán, *J. Am. Chem. Soc.*, 2015, **137**, 3686–3692.
65. I. Lynch and K. A. Dawson, *Nano Today*, 2008, **3**, 40–47.
66. J. Klein, *Proc. Natl. Acad. Sci. U S A*, 2007, **104**, 2029–2030.

67. M. P. Monopoli, C. Åberg, A. Salvati, and K. A. Dawson, *Nat. Nanotechnol.*, 2012, **7**, 779–786.
68. S. Tenzer, D. Docter, J. Kuharev, A. Musyanovych, V. Fetz, R. Hecht, F. Schlenk, D. Fischer, K. Kiouptsi, C. Reinhardt, K. Landfester, H. Schild, M. Maskos, S. K. Knauer, and R. H. Stauber, *Nat. Nanotechnol.*, 2013, **8**, 772–81.
69. A. M. Alkilany, P. K. Nagaria, C. R. Hexel, T. J. Shaw, C. J. Murphy, and M. D. Wyatt, *Small*, 2009, **5**, 701–8.
70. N. Khlebtsov and L. Dykman, *Chem. Soc. Rev.*, 2011, **40**, 1647–71.
71. D. Hühn, K. Kantner, C. Geidel, S. Brandholt, I. De Cock, S. J. H. Soenen, P. Rivera Gil, J.-M. Montenegro, K. Braeckmans, K. Müllen, G. U. Nienhaus, M. Klapper, and W. J. Parak, *ACS Nano*, 2013, **7**, 3253–63.
72. U. Sakulku, L. Maurizi, M. Mahmoudi, M. Motazacker, M. Vries, A. Gramoun, M.-G. O. Beuzelin, J.-P. Vallée, F. Rezaee, and H. Hofmann, *Nanoscale*, 2014, **6**, 11439–11450.
73. C. Passirani, G. Barratt, J.-P. Devissaguet, and D. Labarre, *Life Sci.*, 1998, **62**, 775–785.
74. S. Wan, P. M. Kelly, E. Mahon, H. Stöckmann, F. Caruso, K. A. Dawson, Y. Yan, and M. P. Monopoli, *ACS Nano*, 2015, **9**, 2157–2166.
75. S. Schöttler, G. Becker, S. Winzen, T. Steinbach, K. Mohr, K. Landfester, V. Mailänder, and F. R. Wurm, *Nat. Nanotechnol.*, 2016, **11**, 372–377.
76. C. Lemarchand, R. Gref, and P. Couvreur, *Eur. J. Pharm. Biopharm.*, 2004, **58**, 327–341.
77. J. Virkutyte and R. S. Varma, *Chem. Sci.*, 2011, **2**, 837–846.
78. R. Bandyopadhyaya, E. Nativ-Roth, O. Regev, and R. Yerushalmi-Rozen, *Nano Lett.*, 2002, **2**, 25–28.
79. A. Star, D. W. Steuerman, J. R. Heath, and J. F. Stoddart, *Angew. Chem. Int. Ed. Engl.*, 2002, **41**, 2508–12.
80. R. P. Garay, R. El-Gewely, J. K. Armstrong, G. Garratty, and P. Richette, *Expert Opin Drug Deliv*, 2012, **9**, 1319–23.
81. B. S. Batista, W. S. Eng, K. T. Pilobello, K. D. Hendricks-Muñoz, and L. K. Mahal, *J. Proteome Res.*, 2011, **10**, 4624–33.
82. S. Kooijmans, P. Vader, S. M. van Dommelen, W. W. van Solinge, and R. M. Schiffelers, *Int. J. Nanomedicine*, 2012, **7**, e41.
83. M. Antonietti and S. Förster, *Adv. Mater.*, 2003, **15**, 1323–1333.
84. V. Percec, P. Leowanawat, H.-J. Sun, O. Kulikov, C. D. Nusbaum, T. M. Tran, A. Bertin, D. A. Wilson, M. Peterca, S. Zhang, N. P. Kamat, K. Vargo, D. Moock, E. D. Johnston, D. A. Hammer, D. J. Pochan, Y. Chen, Y. M. Chabre, T. C. Shiao, M. Bergeron-Brlek, S. André, R. Roy, H.-J. Gabius,

- and P. A. Heiney, *J. Am. Chem. Soc.*, 2013, **135**, 9055–77.
85. J. M. Trowbridge and R. L. Gallo, *Glycobiology*, 2002, **12**, 117R–25R.
86. M. A. Skidmore, S. E. Guimond, T. R. Rudd, D. G. Fernig, J. E. Turnbull, and E. A. Yates, *Connect. Tissue Res.*, 2008, **49**, 140–144.
87. M. M. Kemp, A. Kumar, S. Mousa, T.-J. Park, P. Ajayan, N. Kubotera, S. A. Mousa, and R. J. Linhardt, *Biomacromolecules*, 2009, **10**, 589–595.
88. L. W. Place, M. Sekyi, and M. J. Kipper, *Biomacromolecules*, 2014, **15**, 680–689.
89. A. Agostini, L. Mondragón, A. Bernardos, R. Martínez-Máñez, M. D. Marcos, F. Sancenón, J. Soto, A. Costero, C. Manguan-García, R. Perona, M. Moreno-Torres, R. Aparicio-Sanchis, and J. R. Murguía, *Angew. Chem. Int. Ed. Engl.*, 2012, **51**, 10556–60.
90. E. L. Ferguson and R. Duncan, *Biomacromolecules*, 2009, **10**, 1358–1364.
91. T. L. Doane and C. Burda, *Chem. Soc. Rev.*, 2012, **41**, 2885–2911.
92. E. L. Bird-Lieberman, A. A. Neves, P. Lao-Sirieix, M. O'Donovan, M. Novelli, L. B. Lovat, W. S. Eng, L. K. Mahal, K. M. Brindle, and R. C. Fitzgerald, *Nat. Med.*, 2012, **18**, 315–21.
93. X. Gao, J. Chen, J. Chen, B. Wu, H. Chen, and X. Jiang, *Bioconjug. Chem.*, 2008, **19**, 2189–95.
94. J.-H. Liao, C.-T. H. Chien, H.-Y. Wu, K.-F. Huang, I. Wang, M.-R. Ho, I.-F. Tu, I.-M. Lee, W. Li, Y.-L. Shih, C.-Y. Wu, P. A. Lukyanov, S.-T. D. Hsu, and S.-H. Wu, *J. Am. Chem. Soc.*, 2016, **138**, 4787–95.
95. F. Medina-Bolivar, R. Wright, V. Funk, D. Sentz, L. Barroso, T. D. Wilkins, W. Petri, and C. L. Cramer, *Vaccine*, 2003, **21**, 997–1005.